Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
Company research
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a fully integrated, leading biotechnology company headquartered in Tarrytown, New York, founded in 1988 by physician-scientists Leonard Schleifer and George Yancopoulos. The company discovers, invents, develops, manufactures, and commercializes life-transforming medicines targeting a broad range of serious diseases, including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Its commercial portfolio is anchored by blockbuster products such as EYLEA and EYLEA HD for retinal diseases, Dupixent (in collaboration with Sanofi) for atopic dermatitis and asthma, and Libtayo for certain skin cancers, alongside other approved therapies including Praluent, Kevzara, Inmazeb, ARCALYST, and ZALTRAP. Regeneron's competitive edge is driven by its proprietary VelociSuite® technologies for accelerated antibody discovery, deep human genetics capabilities through the Regeneron Genetics Center®, and strategic global partnerships with Sanofi, Bayer, and others, generating approximately $14.2 billion in revenue in FY2024.
Research reports
Ultra Stock Analysis Pro · May 1, 2026Regeneron Pharmaceuticals, Inc. (REGN) - ANALYST REPORT
Quantitative/technical analyst report assigning REGN a HOLD rating but arguing an OVERWEIGHT position is reasonable given 24.8% upside to the $875.31 consensus target, strong 19% revenue growth, solid margins, and very high 91.8% institutional ownership. It emphasizes bullish fundamentals and analyst consensus while flagging technical trend risks and normal biotech competition/volatility, recommending investors wait for stronger technical “confluence” before entry despite the attractive valuation.
StockStory (via Yahoo Finance) · April 29, 2026Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026Earnings-focused research note analyzing Q1 2026, highlighting 19% year-on-year revenue growth to $3.61 billion, an EPS beat to $9.47, and a long-term track record of double-digit revenue growth alongside solid five-year revenue and EPS CAGRs. The piece frames the quarter as a “solid report” but stresses slowing recent growth and margin compression, arguing investors should treat the results positively yet remain selective and valuation-aware rather than viewing one strong quarter as an outright buy signal.
Ultra Stock Analysis Pro · January 25, 2026Regeneron Pharmaceuticals, Inc. (REGN) - Comprehensive Stock Analysis ReportComprehensive technical-and-fundamental report that assigns REGN a WAIT rating with low signal strength, noting neutral RSI, emerging ADX trend, and modest 10.2% upside to the $830.04 average analyst target amid a broadly favorable sell-side consensus (19 Buy, 6 Hold, 1 Sell). It presents a mixed, methodical thesis—fundamentals and analyst targets are supportive, but backtested win rates, volatility profile, and current technical setup lead the authors to recommend staying on the sidelines until a stronger multi-signal technical “confluence” emerges.
Krause Fund, Tippie College Of Business, University Of Iowa · November 18, 2025Regeneron Pharmaceuticals (NYSE: REGN) – Krause Fund Research Fall 2025University student-managed fund report issuing a HOLD recommendation with a $793.23 target versus a $718.33 current price, supported by detailed DCF, dividend discount, and relative valuation work that underscores Regeneron’s strong R&D intensity, diversified high-margin portfolio, and promising growth in Eylea HD, Dupixent, and Libtayo. The thesis is balanced by extensive discussion of patent cliffs, biosimilar competition, Inflation Reduction Act pricing pressure, reliance on collaborations, and sensitivity analyses around revenue retention and cost assumptions, leading to an explicitly “Neutral Outlook” on risk‑adjusted upside.